bionomics-rgb-1024px.png
Bionomics Initiates AFFIRM-1, a Phase 3 Clinical Trial with BNC210 for Social Anxiety Disorder
July 18, 2024 06:30 ET | Bionomics Ltd
Topline results are expected in Q3 2025 ADELAIDE, Australia and CAMBRIDGE, Mass., July 18, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a biotechnology...
bionomics-rgb-1024px.png
Bionomics Limited Announces Private Placement of up to $70.0 Million
May 31, 2024 08:00 ET | Bionomics Ltd
ADELAIDE, Australia and CAMBRIDGE, Mass., May 31, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (“Bionomics” or the “Company”), a clinical-stage biotechnology company developing novel,...
bionomics-rgb-1024px.png
Bionomics to Present at the 2024 American Society of Clinical Psychopharmacology Annual Meeting
May 20, 2024 06:30 ET | Bionomics Ltd
ADELAIDE, Australia and CAMBRIDGE, Mass., May 20, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel,...
bionomics-rgb-1024px.png
Bionomics Reports Results of the Full Dataset Analysis from ATTUNE Phase 2b Trial of BNC210 in Patients with Post-Traumatic Stress Disorder
March 21, 2024 06:00 ET | Bionomics Ltd
BNC210 demonstrated a statistically significant improvement in post-traumatic stress disorder (PTSD) symptom severity with a clinically meaningful effect size suggesting a potential advantage over...
bionomics-rgb-1024px.png
Bionomics to Present at the 2024 BIO CEO & Investor Conference
February 22, 2024 16:30 ET | Bionomics Ltd
ADELAIDE, Australia and CAMBRIDGE, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel,...
bionomics-rgb-1024px.png
Bionomics Provides a Review of 2023 and of 2024 Plans
January 22, 2024 06:00 ET | Bionomics Ltd
Positive Phase 2b data announced for BNC210 on reduction of total symptom severity and multiple symptom clusters in post-traumatic stress disorder (PTSD), with a discussion with the U.S. Food &...
bionomics-rgb-1024px.png
Bionomics to Present at Biotech Showcase™ 2024
January 05, 2024 06:00 ET | Bionomics Ltd
ADELAIDE, Australia and CAMBRIDGE, Mass., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel,...
bionomics-rgb-1024px.png
Bionomics Presents Detailed Data on the Validity and Reliability of the Subjective Units of Distress Scale at the 2023 American College of Neuropsychopharmacology Annual Meeting
December 06, 2023 08:00 ET | Bionomics Ltd
A psychometric analysis concluded that Subjective Units of Distress Scale (SUDS) is a psychometrically valid, sensitive, and reliable tool for evaluation of social anxiety.SUDS will be used as the...
bionomics-rgb-1024px.png
Bionomics Announces Successful End-of-Phase 2 Meeting with the FDA and Solidifies Plans to Initiate the Registrational Program for BNC210 in Social Anxiety Disorder
October 16, 2023 08:00 ET | Bionomics Ltd
Positive outcome of End-of-Phase 2 meeting with U.S. Food and Drug Administration (FDA) in September 2023 enables advancement of BNC210 into Phase 3 studies in Social Anxiety DisorderCompany confirms...
Change from Baseline in CAPS-5 Total Symptom Severity Scores
Bionomics Announces Positive Topline Results from the Phase 2b ATTUNE Clinical Trial of BNC210 in Patients with Post-Traumatic Stress Disorder (PTSD)
September 28, 2023 06:00 ET | Bionomics Ltd
ATTUNE trial met its primary endpoint showing BNC210 treatment led to a statistically significant reduction in total PTSD symptom severity at 12 weeks. Statistically significant secondary endpoints...